Identification

Generic Name
SRP 299
DrugBank Accession Number
DB05440
Background

SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 activity. A specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice.

Type
Small Molecule
Groups
Investigational
Synonyms
Not Available

Pharmacology

Indication

Investigated for use/treatment in asthma, atopic dermatitis, and pediatric atopic dermatitis indications.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Induces peripheral immune activation through the activity of regulatory T-cells

Mechanism of action

Induces activity of regulatory t-cells that surpress Th2 activity. CD11c+ cells act as the primary target for M. vaccae.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of SRP 299 can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of SRP 299 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Arkwright PD, Fujisawa C, Tanaka A, Matsuda H: Mycobacterium vaccae reduces scratching behavior but not the rash in NC mice with eczema: a randomized, blinded, placebo-controlled trial. J Invest Dermatol. 2005 Jan;124(1):140-3. [Article]
  2. Breivik T, Rook GA: Oral treatment with SRP299 (killed Mycobacterium vaccae) inhibits experimental periodontal disease in Wistar rats. J Clin Periodontol. 2003 Nov;30(11):931-6. [Article]
PubChem Substance
347910140

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 18, 2007 18:25 / Updated at June 12, 2020 16:52